PALI stock plunges to 52-week low, hitting $0.74

PALI Pharmaceuticals experienced a significant downturn as its stock value tumbled to $0.74 USD, near its 52-week low. According to InvestingPro analysis, the company appears undervalued at its current market capitalization of $2 million. This latest price point reflects a stark contrast to the company’s performance over the past year, which has seen a precipitous decline. In a broader context, the stock has undergone a dramatic 1-year change, plummeting by -87.12%. The company’s EBITDA stands at -$14.4 million, though analyst price targets range from $8 to $38, suggesting potential recovery opportunities. Investors are closely monitoring PALI’s financial health and market position, as the company grapples with the challenges that have led to this notable low in its stock valuation. InvestingPro subscribers can access 14 additional key insights about PALI’s financial health and future prospects.

In other recent news, Palisade Bio, Inc. has announced the completion of the Single Ascending Dose stage of its Phase 1a/b study for PALI-2108, a drug candidate for ulcerative colitis, indicating the treatment was well-tolerated across various dosages without serious adverse effects. The company is advancing to the Multiple Ascending Dose phase, with topline data expected in the first half of 2025. Additionally, Palisade Bio secured 1.39 million Canadian dollars in Scientific Research and Experimental Development tax credits from Canada, aimed at reimbursing prior pre-clinical costs associated with PALI-2108. This funding supports the ongoing development of the drug, which is also being co-developed with Giiant Pharma, Inc. Furthermore, Palisade Bio is set to present data from its lead program PALI-2108 at Digestive Disease Week 2025, showcasing its research on the drug’s potential efficacy in treating ulcerative colitis. The company’s abstract has been recognized among the top 10% for presentation at the conference. Investors are advised to consider the risks and uncertainties detailed in Palisade Bio’s SEC filings as the company continues its clinical trials and seeks regulatory approval.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.